Skip to main content

Table 6 Factors associated with the recurrence of HCC after DAA treatment in the late phase (more than 1 year after DAA treatment completion)

From: AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

 

HCC recurrence

No HCC recurrence

Hazard ratio

95% CI

p-value

Age (years)

73.5 ± 7.0

70.6 ± 8.1

1.04

0.99–1.08

0.062

Sex (male/female)

29/10

48/39

2.15

1.04–4.42

0.049

Body mass index (kg/m2)

23.1 ± 3.2

23.3 ± 3.6

0.97

0.88–1.07

0.79

White blood cell count (/μL)

4435 ± 1641

4311 ± 1250

1.00

0.99–1.00

0.64

Platelet count (×104/μL)

14.8 ± 15.2

11.4 ± 4.6

1.01

0.99–1.03

0.064

ALT (U/L)

45.6 ± 26.1

46.7 ± 29.1

0.99

0.98–1.00

0.84

AST (U/L)

50.7 ± 22.3

52.2 ± 28.5

0.99

0.98–1.00

0.76

Total bilirubin (mg/dL)

0.8 ± 0.4

0.8 ± 0.4

0.75

0.35–1.60

0.80

Albumin (g/dL)

3.8 ± 0.4

3.8 ± 0.4

1.05

0.48–2.28

0.79

Prothrombin time (%)

85.1 ± 15.5

81.6 ± 16.6

1.01

0.99–1.03

0.28

AFP (ng/mL)

12.2 ± 14.8

17.6 ± 40.9

0.99

0.97–1.01

0.43

eGFR (mL/min/1.73 m2)

65.1 ± 18.3

71.6 ± 19.4

0.98

1.00–1.02

0.020

Total cholesterol (mg/dL)

152 ± 23

151 ± 26

1.00

0.99–1.02

0.85

Diabetes mellitus (no/yes)

26/12

70/17

1.77

0.89–3.51

0.16

Alcohol (none/drinking/unknown)

32/6/1

62/12/3

1.29

0.74–2.25

0.23

FIB-4 index

4.9 ± 2.5

5.7 ± 3.7

0.89

0.78–1.01

0.24

APRI

1.2 ± 0.7

1.5 ± 1.6

0.65

0.41–1.02

0.24

Post-treatment white blood cell count (/μL)

4964 ± 1465

4710 ± 1606

1.00

0.99–1.00

0.41

Post-treatment ALT (U/L)

21.5 ± 11.9

25.0 ± 31.6

0.99

0.97–1.01

0.52

Post-treatment AST (U/L)

28.4 ± 15.5

30.5 ± 20.6

0.98

0.96–1.01

0.58

Post-treatment total bilirubin (mg/dL)

0.8 ± 0.4

0.8 ± 0.4

0.78

0.35–1.73

0.98

Post-treatment albumin (g/dL)

3.9 ± 0.4

3.9 ± 0.3

1.03

0.48–2.21

0.61

Post-treatment prothrombin time (%)

84.3 ± 13.9

82.8 ± 17.3

1.00

0.98–1.02

0.67

Post-treatment AFP (ng/mL)

6.0 ± 5.3

6.6 ± 6.6

0.97

0.90–1.05

0.69

Post-treatment eGFR (mL/min/1.73 m2)

62.7 ± 19.6

70.6 ± 17.0

0.98

0.96–0.99

0.013

SVR/no SVR

38/1

84/3

0.78

0.10–5.73

1.00

Child-Pugh class (A/B/C)

32/4/0

71/12/0

0.68

0.24–1.93

0.77

BCLC stage (0/A/B/C/D)

19/9/4/6/1

39/20/12/15/1

0.97

0.74–1.28

0.94

Number of months from HCC treatment to DAA therapy initiation

25 ± 34

21 ± 23

1.00

0.99–1.00

0.51

Number of curative treatments for HCC

1.0 ± 1.2

0.8 ± 1.4

1.13

0.89–1.43

0.44